Key Highlights

  • Veracyte shares closed at $48.54 today, up 10.77%, on Volume more than 1.6 times average.
  • Second-quarter results beat expectations with adjusted Earnings Per Share of $0.54, up 25.6% versus consensus, and Revenue of $150.3 million.
  • The company raised its full-year outlook following the strong quarter.
  • Investors are also digesting the company's recent $150 million Acquisition of Convergent Genomics, which expands its urology diagnostics portfolio with a urinary tumor DNA testing platform.

Strong Earnings Beat Extends a Multi-Session Rally

Veracyte (NASDAQ:VCYT) shares surged on heavy volume today, more than 1.6 times average, extending a multi-session rally built on strong underlying fundamentals. Second-quarter results beat expectations with adjusted earnings per share of $0.54, up 25.6% compared with consensus estimates, and revenue of $150.3 million, prompting the company to raise its full-year outlook.

Convergent Genomics Acquisition Expands Urology Portfolio

Investors are also digesting the company's recent $150 million acquisition of Convergent Genomics, which expands Veracyte's urology diagnostics portfolio with a urinary tumor DNA testing platform. Bullish analyst commentary has followed the news, with one firm raising its price target to $69 and another to $66, and the stock recently earned a top ranking from a well-known stock-screening service, even as some insider selling and mixed valuation signals from other models provide a note of caution.

A Global Genomic Diagnostics Leader

Veracyte is a global genomic diagnostics company headquartered in South San Francisco, California, dedicated to transforming cancer care through advanced molecular testing. Its diagnostic portfolio includes the Afirma Genomic Sequencing Classifier for thyroid nodules, the Decipher Prostate and Bladder Genomic Classifiers, and the Percepta Nasal Swab Test for lung cancer, each designed to help clinicians make confident, evidence-based treatment decisions across testing performed at its CLIA-certified laboratories and through third-party diagnostic instruments.